What It Is
Flow FL-100 is a prescription-only, at-home transcranial direct current stimulation (tDCS) headset developed by Flow Neuroscience. It received full FDA premarket approval (PMA) on December 8, 2025, and is scheduled for US release on September 1, 2026. It is the first at-home, non-invasive brain stimulation device cleared by the FDA specifically for treating major depressive disorder.
The device can be used as standalone monotherapy (without medication) or as an adjunct alongside antidepressants for patients who are not considered treatment-refractory.
How It Works
Flow FL-100 delivers a low-intensity electrical current (typically 1-2 mA) through electrodes placed on the forehead, targeting the left dorsolateral prefrontal cortex (DLPFC) — a brain region consistently shown to be underactive in people with depression. The stimulation is thought to increase neuronal excitability in this region, helping to rebalance activity between the left and right prefrontal cortices.
Treatment protocol:
- Weeks 1-3: 30-minute sessions, 5 times per week (acute phase)
- Weeks 4-10: 30-minute sessions, 3 times per week (maintenance phase)
- Sessions are self-administered at home using a companion app
The tDCS approach is fundamentally different from transcranial magnetic stimulation (TMS), which requires clinical office visits and uses magnetic pulses rather than direct current. Flow FL-100 makes brain stimulation accessible outside the clinic for the first time with FDA backing.
The Clinical Evidence
The FDA approval was supported by the Empower trial (NCT05202119), a multi-site, double-blind, randomized, sham-controlled study — the gold standard for medical device evaluation.
Key results:
- 174 participants with major depressive disorder
- 57.5% remission rate in the active treatment group by week 10
- Statistically significant improvement in depression scores vs sham
- Safety: Minimal side effects — primarily mild skin irritation and headache. No serious adverse events reported
- 10-week treatment duration with at-home administration
Context: A 57.5% remission rate is competitive with first-line antidepressant medications, which typically achieve 30-40% remission in clinical trials. The combination of efficacy, safety, and home administration makes this a potentially significant treatment option.
What we don't know: Long-term maintenance protocols beyond 10 weeks, relapse rates after discontinuation, and head-to-head comparison with medication remain to be studied.
Who It's For
Flow FL-100 is indicated for adults with moderate to severe major depressive disorder who are not treatment-refractory (meaning they have not failed multiple medication trials). It requires a prescription from a licensed healthcare provider.
It is not a wellness device, a meditation aid, or a general cognitive enhancer. It is a regulated medical treatment for a specific clinical condition.
What It Costs
US pricing has not been formally announced as of August 2026. In the European market (where Flow has been available since 2019 under CE marking), the device has been priced around €399 with a monthly subscription for the therapy app. US pricing may differ, and insurance/reimbursement pathways are being established.
The Body-Mind Perspective
Flow FL-100 adds a non-pharmacological option for practitioners whose clients struggle with depression. The DLPFC region it targets is the same area activated during focused attention meditation, cognitive reappraisal, and executive function tasks — suggesting potential synergy between tDCS and mindfulness-based practices.
For body-mind practitioners, the key insight is that the device addresses a specific neurological deficit (prefrontal underactivity in depression) rather than providing general brain stimulation. This precision makes it a legitimate clinical tool rather than another "brain zapping" gimmick. However, it treats one dimension of depression and does not address the somatic, relational, or autonomic factors that body-mind approaches target.
Bottom Line
Evidence strength: Strong. Full FDA PMA (the highest level of device approval), 174-person sham-controlled trial, 57.5% remission rate, and favorable safety profile. The clinical evidence for the Flow FL-100 is among the strongest in the at-home neuromodulation category. The main limitation is the relatively small trial size and the need for longer-term follow-up data.
Source
- FDA Premarket Approval — Flow FL-100. — U.S. Food and Drug Administration
- Empower Trial (NCT05202119). — ClinicalTrials.gov
